Allosteric TORC1 inhibitors exert an anticancer activity and were shown to sensitize cancer cells to the conventional EBRT in various cancer models, including Ras-transformed cells [70], advanced renal carcinoma [71], breast cancer [72], PTEN-null prostate cancer cells [73] and, more recently, in all five tested neuroendocrine neoplasm (NEN) cell lines [74]. Here, PTEN is linked to cancer.